The company leaves the door open for Trodelvy pre-chemo, despite Ascent-07’s failure.
ApexOnco Front Page
Recent articles
Giredestrant’s adjuvant benefit looks similar to that of Kisqali and Verzenio.
Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.
The upcoming Rasolute-304 trial will compare daraxonrasib versus observation.
With a phase 3 trial of the trispecific T-cell engager ramantamig, J&J will challenge itself.
Though lung cancer looks promising a partner is now needed.
The company’s AN9025 will shortly enter phase 1.
